Compare Keysight Technologies Inc (KEYS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Pfizer Inc — how do they compare? Keysight Technologies Inc trades at $328.02 (market cap $53.68B), while Pfizer Inc trades at $24.83 (market cap $141.06B). The key difference: Pfizer Inc is far larger — about 2.6× Keysight Technologies Inc's market cap, and Pfizer Inc pays a 6.95% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals.
| KEYS | PFE | |
|---|---|---|
Market Cap | $53.68B | $141.06B |
Sector | Technology | Health |
52-Week High | $373.34 | $28.56 |
52-Week Low | $158.51 | $23.29 |
Enterprise Value | $54.03B | $191.72B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $313.97, down 0.61% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong profitability with a 17.31% net margin and has secured strategic partnerships, including a European Space Agency contract for 5G network development announced July 15, 2026. Analyst consensus remains strongly bullish with an $396.56 price target, though valuation multiples appear elevated with a P/E of 50.87.
KEYS presents a growth opportunity driven by AI and 5G testing demand, but faces risks from high valuation and volatile cash flows. The stock's near-term direction hinges on Q2 2026 earnings versus the $2.46 EPS estimate, with support at $309 critical for maintaining bullish technical structure.
Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a bullish technical signal supported by strong quarterly earnings beats. The company maintains solid profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated post-pandemic. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning PFE for potential growth catalysts in 2026.
The outlook for Pfizer is cautiously optimistic, with a consensus price target of $28.25 offering 13% upside. Key opportunities include dividend stability and pipeline innovation, while risks involve patent cliffs and competitive pressures. Analyst sentiment is mixed with 38% buy ratings, reflecting balanced views on recovery potential versus near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
